The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan
Crossref DOI link: https://doi.org/10.1186/s13063-017-1976-6
Published Online: 2017-05-23
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chen, Tao
Chan, Susan
Lack, Gideon
Cro, Suzie
Cornelius, Victoria R.
Funding for this research was provided by:
Efficacy and Mechanism Evaluation Programme (11/14/24)